ID | 1048 |
Name of the vaccine | Pediarix |
Microbe | Bacteria |
Disease name | Pertussis (Whooping Cough) |
Name of bacteria | Bordetella pertussis |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | 6 weeks to 6 years |
Description of the vaccine | Diphtheria, Tetanus Toxoids, Acellular Pertussis adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus vaccine. |
Name of the manufacturer | GlaxoSmithKline Biologicals and GSK Vaccines GmbH |
Name of the manufacturing country | Belgium and Germany |
Year of manufacture | 2002 |
Clinical Phase status | Approved |
Bacterial strain | Gram-negative coccobacillus. |
Efficacy | Was determined in clinical trials of Infanrix. |
Vaccine formulation | Suspension for injection |
Dosage | Three doses (0.5-mL each) at 2, 4, and 6 months of age. |
Mechanism of action | No established serological correlate of protection for pertussis. |
Route of administration | Intramuscular |
Indications | Active immunization against diphtheria, tetanus, pertussis, all known subtypes of hepatitis B virus, and poliomyelitis. |
Export | Distributed by - GlaxoSmithKline |
Approval | US FDA |
Adjuvant | Aluminium salts |
Repurposing | Could be used for diphtheria and tetanus. |
Side effects of vaccine | Pain, redness, and swelling, fever, drowsiness, irritability and loss of appetite. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/79830/download |
Other name | NA |
Additional Links | https://www.drugs.com/pediarix.html
|